Abstract
Moexipril is a long-acting, non-sulfhydryl angiotensine-converting enzyme inhibitor. It is used for treatment of arterial hypertension. Moexipril is the prodrug, yielding moexiprilat by hydrolysis of an ethyl ester group. Moexiprilat is the metabolite responsible for the pharmacological effect after moexipril administration. Samples of rat and human microsomai preparations exposed to moexipril treatment were analyzed by HPLC using octyl silica stationary phase and isocratic elution. To detect moexipril and moexiprilat the separation was monitored by both ultraviolet and mass specific detection. The rat liver microsomal preparation was more effective to in producing moexiprilat than the similar one derived from human liver cell lines. While additional potential metabolites of moexipril were suggested by computer-modeling, moexiprilat was the sole metabolite detected after microsomal treatment.
Keywords: Moexipril metabolism, moexiprilat, microsomal, HPLC-ES-MS, isocratic elution
Medicinal Chemistry
Title: Metabolism of Moexipril to Moexiprilat: Determination of In Vitro Metabolism Using HPLC-ES-MS
Volume: 3 Issue: 1
Author(s): H. Kalasz, G. Petroianu, K. Tekes, I. Klebovich, K. Ludanyi and Zs. Gulyas
Affiliation:
Keywords: Moexipril metabolism, moexiprilat, microsomal, HPLC-ES-MS, isocratic elution
Abstract: Moexipril is a long-acting, non-sulfhydryl angiotensine-converting enzyme inhibitor. It is used for treatment of arterial hypertension. Moexipril is the prodrug, yielding moexiprilat by hydrolysis of an ethyl ester group. Moexiprilat is the metabolite responsible for the pharmacological effect after moexipril administration. Samples of rat and human microsomai preparations exposed to moexipril treatment were analyzed by HPLC using octyl silica stationary phase and isocratic elution. To detect moexipril and moexiprilat the separation was monitored by both ultraviolet and mass specific detection. The rat liver microsomal preparation was more effective to in producing moexiprilat than the similar one derived from human liver cell lines. While additional potential metabolites of moexipril were suggested by computer-modeling, moexiprilat was the sole metabolite detected after microsomal treatment.
Export Options
About this article
Cite this article as:
Kalasz H., Petroianu G., Tekes K., Klebovich I., Ludanyi K. and Gulyas Zs., Metabolism of Moexipril to Moexiprilat: Determination of In Vitro Metabolism Using HPLC-ES-MS, Medicinal Chemistry 2007; 3 (1) . https://dx.doi.org/10.2174/157340607779317490
DOI https://dx.doi.org/10.2174/157340607779317490 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biological Mechanisms Linking Alzheimer's Disease and Type-2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Inhibition of Receptor Tyrosine Kinases in Combination with Chemotherapy for the Treatment of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Anti-VEGF Therapy for Retinal Vein Occlusions
Current Drug Targets Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450
Current Drug Metabolism Flavonoid-Enriched Extract from Desert Plant Warionia saharae Improves Glucose and Cholesterol Levels in Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Impact of Antihypertensive Drug Use on Bone Mineral Density and Osteoporotic Fracture - From an Epidemiological Perspective
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Mesenchymal Stem Cells Induced In Vitro Generated Regulatory-T Cells: Potential Soldiers of Transplantation Biology
Current Biotechnology Patent Annotations
Recent Patents on Cardiovascular Drug Discovery Metabolic Control and Diabetic Retinopathy
Current Diabetes Reviews Impaired Neurovascular Coupling in the APPxPS1 Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Protective Effect of Dietary Potassium against Cardiovascular Damage in Salt-Sensitive Hypertension: Possible Role of its Antioxidant Action
Current Vascular Pharmacology Arterial Hypertension and Multiple Myeloma: Physiopathology and Cardiovascular Risk and ‘Practical’ Indications in Patients Receiving Carfilzomib
Current Hypertension Reviews VDAC-Targeted Drugs Affecting Cytoprotection and Mitochondrial Physiology in Cerebrovascular and Cardiovascular Diseases
Current Medicinal Chemistry Renin Angiotensin System and Cytokines in Chronic Kidney Disease: Clinical and Experimental Evidence
Protein & Peptide Letters Extensive Coronary Calcification: A Clinically Unrecognised Condition
Current Vascular Pharmacology Combination Therapy with Chinese Medicine and ACEI/ARB for the Management of Diabetic Nephropathy: The Promise in Research Fragments
Current Vascular Pharmacology Significance of High Levels of Endogenous Melatonin in Mammalian Cerebrospinal Fluid and in the Central Nervous System
Current Neuropharmacology Pharmacology of Nitric Oxide: Molecular Mechanisms and Therapeutic Strategies
Current Pharmaceutical Design Practical Application of Antidiabetic Efficacy of <i>Lycium barbarum</i> Polysaccharide in Patients with Type 2 Diabetes
Medicinal Chemistry Prevention of Ischemic Stroke: Overview of Traditional Risk Factors
Current Drug Targets